Sodium bicarbonate

Identification

Summary

Sodium bicarbonate is a compound used for the symptomatic treatment of heartburn, acid indigestion, and upset stomach as well as the treatment of metabolic acidosis associated with conditions such as severe renal disease and circulatory insufficiency due to shock.

Brand Names
Alka-seltzer, Alka-seltzer Fruit Chews, Alka-seltzer Heartburn Relief, Bi-peglyte, Bibag, Bicart, Bss Ophthalmic Solution, Ceo-two, Colyte, Gavilyte-C, Gavilyte-G, Gavilyte-H and Bisacodyl, Gavilyte-N, Golytely, H.E.L.P.bicel, Hema Bp-38, Hemacart, Konvomep, Nulytely, Peglyte, Phoxillum, Physioneal 40, Prismasol, Zegerid, Zegerid Reformulated Aug 2006, Zegerid With Magnesium Hydroxide
Generic Name
Sodium bicarbonate
DrugBank Accession Number
DB01390
Background

Sodium bicarbonate is a white, crystalline powder that is commonly used as a pH buffering agent, an electrolyte replenisher, systemic alkalizer and in topical cleansing solutions.

Type
Small Molecule
Groups
Approved
Structure
Weight
Average: 84.0066
Monoisotopic: 83.982338573
Chemical Formula
CHNaO3
Synonyms
  • Baking soda
  • Bicarbonate of soda
  • Carbonic acid monosodium salt
  • NaHCO3
  • Natriumhydrogenkarbonat
  • Sodio bicarbonato
  • Sodium acid carbonate
  • Sodium bicarbonate
  • Sodium hydrogen carbonate
  • Sodium hydrogencarbonate
External IDs
  • B1654
  • E 500
  • E-500
  • E-500(II)
  • E500
  • INS NO.500(II)
  • INS-500(II)

Pharmacology

Indication

Sodium bicarbonate is used for the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturateprotein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of blood pigments.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Symptomatic treatment ofAcid indigestion••• •••
Management ofBarbiturate intoxication••••••••••••
Used in combination as diagnostic agentBreast cancerCombination Product in combination with: Tetrofosmin (DB11180)••••••••••••••••••••• ••••••• ••• ••••••••
Used in combination to treatConstipationCombination Product in combination with: Potassium bitartrate (DB11107)••• ••••••••••••••
Prophylaxis ofContrast-induced nephropathy••• •••••
Associated Therapies
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Intravenous sodium bicarbonate therapy increases plasma bicarbonate, buffers excess hydrogen ion concentration, raises blood pH and reverses the clinical manifestations of acidosis.

Mechanism of action

Sodium bicarbonate is a systemic alkalizer, which increases plasma bicarbonate, buffers excess hydrogen ion concentration, and raises blood pH, thereby reversing the clinical manifestations of acidosis. It is also a urinary alkalizer, increasing the excretion of free bicarbonate ions in the urine, thus effectively raising the urinary pH. By maintaining an alkaline urine, the actual dissolution of uric acid stones may be accomplished. Sodium bicarbonate acts as an antacid and reacts chemically to neutralize or buffer existing quantities of stomach acid but has no direct effect on its output. This action results in increased pH value of stomach contents, thus providing relief of hyperacidity symptoms. [PharmGKB]

TargetActionsOrganism
AHydrogen ions
neutralizer
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Sodium bicarbonate.
AcetophenazineSodium bicarbonate can cause a decrease in the absorption of Acetophenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Alendronic acidThe serum concentration of Alendronic acid can be decreased when it is combined with Sodium bicarbonate.
AlimemazineSodium bicarbonate can cause a decrease in the absorption of Alimemazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
AllopurinolThe therapeutic efficacy of Allopurinol can be decreased when used in combination with Sodium bicarbonate.
Food Interactions
  • Take with or without food. Many different products contain sodium bicarbonate; refer to the product monograph for more specific instruction.

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Active Moieties
NameKindUNIICASInChI Key
Sodium cationionicLYR4M0NH3717341-25-2FKNQFGJONOIPTF-UHFFFAOYSA-N
Carbon dioxideunknown142M471B3J124-38-9CURLTUGMZLYLDI-UHFFFAOYSA-N
Bicarbonate ionionicHN1ZRA3Q2071-52-3BVKZGUZCCUSVTD-UHFFFAOYSA-M
Product Images
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
7.5% Sodium BicarbonateInjection, solution75 mg/1mLIntravenousHF Acquisition Co LLC, DBA HealthFirst2020-01-29Not applicableUS flag
8.4% Sodium BicarbonateInjection, solution84 mg/1mLIntravenousHF Acquisition Co. LLC, DBA HealthFirst2018-09-01Not applicableUS flag
800 Sodium Bicarbonate PowderPowder, for solution650 g / 8 LHemodialysisBaxter Laboratories1988-12-31Not applicableCanada flag
BibagPowder, for solution900 g / bagHemodialysisFresenius Medical Care Korea2020-01-30Not applicableCanada flag
BibagPowder, for solution650 g / bagHemodialysisFresenius Medical Care Korea2009-12-10Not applicableCanada flag
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Sodium BicarbonateInjection, solution84 mg/1mLIntravenousMedical Purchasing Solutions, Llc2019-08-01Not applicableUS flag
Sodium BicarbonateInjection, solution42 mg/1mLIntravenousHenry Schein, Inc.2023-05-08Not applicableUS flag
Sodium BicarbonateInjection84 mg/1mLIntravenousHF Acquisition Co LLC, DBA HealthFirst2020-05-18Not applicableUS flag
Sodium BicarbonateInjection, solution42 mg/1mLIntravenousHenry Schein, Inc.2022-01-12Not applicableUS flag
Sodium BicarbonateInjection, solution42 mg/1mLIntravenousHospira, Inc.2020-08-17Not applicableUS flag
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
After Bite AdvancedLiquid50 mg/1mLTopicalAdventure Ready Brands2021-01-01Not applicableUS flag
After Bite AdvancedLiquid50 mg/1mLTopicalAdventure Ready Brands2020-09-012023-12-31US flag
After Bite KidsLiquid5 g/100gTopicalTender Corporation2014-11-262020-09-30US flag
After Bite KidsLiquid5 g/100gTopicalAdventure Ready Brands2020-09-01Not applicableUS flag
After Bite SensitiveLiquid5 g/100gTopicalTender Corporation2014-11-26Not applicableUS flag
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
ACCUSOL 35Sodium bicarbonate (12.9 g/L) + Calcium chloride dihydrate (0.343 g/L) + Magnesium chloride hexahydrate (0.136 g/L) + Sodium chloride (7.66 g/L)Solutionบริษัท ซิลลิค ฟาร์มา จำกัด2015-08-31Not applicableThailand flag
ACIFREE® DOBLE ACCIÓNSodium bicarbonate (2.13 g) + Sodium alginate (5 g) + Calcium carbonate (3.25 g)SuspensionOralLABORATORIOS DEMAC LTDA.2019-12-03Not applicableColombia flag
Adea GargleSodium bicarbonate (36.2 g/100mg) + Xylitol (5 g/100mg)Tablet, chewableOralK2resource Co., Ltd.2018-03-01Not applicableUS flag
Adea GargleSodium bicarbonate (36.2 g/100mg) + Xylitol (5 g/100mg)Tablet, chewableOralK2resource Co., Ltd.2018-03-012018-04-01US flag
AGRILAX SUSPENSIONSodium bicarbonate (2.67 g) + Sodium alginate (2.5 g)SuspensionOralCOLOMPACK S.A.2012-09-03Not applicableColombia flag
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
7.5% Sodium BicarbonateSodium bicarbonate (75 mg/1mL)Injection, solutionIntravenousHF Acquisition Co LLC, DBA HealthFirst2020-01-29Not applicableUS flag
8.4% Sodium BicarbonateSodium bicarbonate (84 mg/1mL)Injection, solutionIntravenousHF Acquisition Co. LLC, DBA HealthFirst2018-09-01Not applicableUS flag
Adea GargleSodium bicarbonate (36.2 g/100mg) + Xylitol (5 g/100mg)Tablet, chewableOralK2resource Co., Ltd.2018-03-012018-04-01US flag
Adea GargleSodium bicarbonate (36.2 g/100mg) + Xylitol (5 g/100mg)Tablet, chewableOralK2resource Co., Ltd.2018-03-01Not applicableUS flag
All natural Saline Packets CareOneSodium bicarbonate (700 mg/3000mg) + Sodium chloride (2300 mg/3000mg)Powder, for solutionNasalFoodhold U.S.A.2022-01-08Not applicableUS flag

Categories

ATC Codes
B05CB04 — Sodium bicarbonateB05XA02 — Sodium bicarbonate
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as organic carbonic acids. These are compounds comprising the carbonic acid functional group.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Organic carbonic acids and derivatives
Sub Class
Organic carbonic acids
Direct Parent
Organic carbonic acids
Alternative Parents
Carbonate salts / Organic sodium salts / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Substituents
Aliphatic acyclic compound / Carbonate salt / Carbonic acid / Carbonyl group / Hydrocarbon derivative / Organic alkali metal salt / Organic oxide / Organic oxygen compound / Organic salt / Organic sodium salt
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
one-carbon compound, organic sodium salt (CHEBI:32139)
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
8MDF5V39QO
CAS number
144-55-8
InChI Key
UIIMBOGNXHQVGW-UHFFFAOYSA-M
InChI
InChI=1S/CH2O3.Na/c2-1(3)4;/h(H2,2,3,4);/q;+1/p-1
IUPAC Name
sodium hydrogen carbonate
SMILES
[Na+].OC([O-])=O

References

Synthesis Reference

Alan B. Gancy, Rustom P. Poncha, "Production of low bulk density product from sodium bicarbonate by the use of an inert gas stream." U.S. Patent US3984527, issued August, 1922.

US3984527
General References
  1. TITCK Product Information: ENHOŞ MEYVE TUZU (tartaric acid/sodium bicarbonate) effervescent powder [Link]
  2. INVIMA Product Authorization: Lua Plus Fruit Salt (simeticone/sodium bicarbonate) oral granules [Link]
  3. AIFA Package Leaflet: TETROFOSMINA ROTOP (sodium bicarbonate and tetrofosmin) intravenous kit [Link]
  4. FDA Approved Drug Products: KONVOMEP™ (omeprazole and sodium bicarbonate for oral suspension) [Link]
Human Metabolome Database
HMDB0303541
KEGG Drug
D01203
KEGG Compound
C12603
PubChem Compound
516892
PubChem Substance
46507049
ChemSpider
8609
RxNav
36676
ChEBI
32139
ChEMBL
CHEMBL1353
Therapeutic Targets Database
DAP000128
PharmGKB
PA451375
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Sodium_bicarbonate
MSDS
Download (74 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4Active Not RecruitingHealth Services ResearchColorectal Cancer1
4CompletedNot AvailableColonoscopy1
4CompletedNot AvailableNormal Healthy Subject Population1
4CompletedNot AvailablePain of Anesthesia at Breast Biopsy1
4CompletedDiagnosticAnatomic renal artery stenosis / Chronic Kidney Disease (CKD) / Lung Cancer / Pulmonary Embolism1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • Alaven Pharmaceutical
  • Alcon Laboratories
  • American Regent
  • Amphastar Pharmaceuticals
  • APP Pharmaceuticals
  • A-S Medication Solutions LLC
  • Atlantic Biologicals Corporation
  • B. Braun Melsungen AG
  • C.O. Truxton Inc.
  • Cardinal Health
  • Claris Lifesciences Inc.
  • Concord Labs
  • Consolidated Medical Imaging
  • Cura Pharmaceutical Co. Inc.
  • Dispensing Solutions
  • Fresenius Kabi AB
  • General Injectables and Vaccines Inc.
  • Hospira Inc.
  • Humco
  • Luitpold Pharmaceuticals Inc.
  • Mckesson Corp.
  • Mylan
  • Norwich Pharmaceuticals Inc.
  • Physicians Total Care Inc.
  • Prasco Labs
  • QOL Medical
  • Sandhills Packaging Inc.
  • Santarus Inc.
Dosage Forms
FormRouteStrength
Powder, for solutionHemodialysis650 g / 8 L
SolutionHemodialysis0.257 g/1000ml
LiquidTopical50 mg/1mL
LiquidTopical5 g/100g
SwabTopical50 mg/1mL
LiquidTopical50 mg/1000mL
Tablet, effervescentOral
TabletOral324 mg
Injection, powder, for suspensionHemodialysis750 mg
Powder, for solutionIntraocular
LiquidTopical
LiquidTopical5 g/100mL
SolutionIntravenous
InjectionIntravenous
SolutionHemodialysis; Topical8.4 g
CreamTopical4.5 g/90mL
PowderOral100 %
Powder, for solutionOral100 g
GranuleOral460 mg/g
Powder, for solutionHemodialysis
SolutionIntravenous0.750 g
Kit; powder, for solution; tablet, delayed releaseOral
Powder, for solutionHemodialysis650 g / bag
Powder, for solutionHemodialysis900 g / bag
Powder, for solutionExtracorporeal100 %
Powder, for solutionHemodialysis100 g
Powder, for solutionHemodialysis100 %
Injection, powder, for solutionHemodialysis100 g
LiquidHemodialysis81.25 g / L
LiquidHemodialysis72 g / L
LiquidHemodialysis80.68 g / L
SolutionHemodialysis80.7 g / L
SolutionHemodialysis81.3 g / L
LiquidHemodialysis
SolutionIntravenous0.8401 g
SolutionIntravenous840 mg
SolutionIntravenous0.84 g
SolutionParenteral840 mg
Injection, powder, lyophilized, for solutionHemodialysis8.125 g
SolutionIntravenous840.1 mg
PowderHemodialysis1250 g / cartridge
PowderHemodialysis650 g / cartridge
PowderHemodialysis720 g / cartridge
Kit; powder, for solutionHemodialysis
Powder, for solutionHemodialysis750 g / cartridge
Powder, for solutionHemodialysis900 g / cartridge
SolutionHemodialysis; Intravenous
SolutionHemodialysis; Intravenous0.187 g/L
SolutionOther
Granule, effervescentOral
Granule, effervescentOral1.02 g/5g
Granule, effervescentOral1.8 g / 6 g
Granule, effervescentOral269 mg / g
Concentrate; kit; solutionOphthalmic
Kit; solutionIntraocular
LiquidOphthalmic
LiquidIntravenous
SuppositoryRectal
KitIntravenous
Powder, for solutionNasogastric
SolutionHemodialysis; Topical6.5527 g
Solution, concentrateHemodialysis
Injection, powder, lyophilized, for solutionHemodialysis
Kit; powderNasal
PowderNasal
Powder, for solutionHemodialysis650 g / pck
Drug delivery systemOral105.00 g
LiquidOral525 mg/15mL
SolutionParenteral8.4 g
SolutionIntravenous3.750 g
InjectionIntravenous84 mg/ml
SolutionIntravenous4.21 g/1000ml
LiquidOral25 mg/1mL
Injection, solutionIntravenous
SolutionIntravenous750.00 mg
InjectionIntrathecal
Injection, solutionIntraperitoneal
Granule, for solutionOral64 g
GranuleHemodialysis100 g
Tablet, delayed releaseOral1000 MG
SuspensionOral325 MG/10ML
Tablet, chewableOral187.5 MG
SuspensionOral160 MG/10ML
Tablet, chewableOral80 MG
Tablet, chewableBuccal
Powder, for solutionOral1 g/1g
Powder, for solutionNasogastric; Oral
PowderTopical165 g/300g
SolutionHemodialysis
KitOral
SolutionHemodialysis66 g/l
Powder6 kg / container
Powder, for solutionHemodialysis650 g / cartridge
Solution, concentrateHemodialysis8.4 g/100mL
Solution, concentrateIntravenous8.4 g/100mL
SolutionHemodialysis8.4 g
Injection, solutionIntravenous8.4 %
PowderOral1000 mg/1g
GranuleOral
Kit; solution; suspensionOral
TabletTopical60 g/100g
TabletTransmucosal
Injection
SuspensionOral
SolutionIntravenous0.84 g/10ml
Powder, for solutionOral13.125 g
Powder, for solutionOral13.125 G
Injection, solution, concentrateOral
SolutionIntravenous4.410 g
Injection, solutionHemodialysis; Intravenous
SolutionIntravenous1.68 g
Injection, solution, concentrateParenteral8.4 %
Capsule, delayed releaseOral500 mg
Kit; solutionIntraocular; Irrigation
Capsule, delayed releaseOral840 mg
Injection, solutionIntravenous0.2 g/5mL
TabletOral
For suspensionOral
Powder, for suspensionOral
Liquid; mouthwashOral
PasteDental
Injection, solutionIntramuscular84 mg/1mL
PowderOral238.33 g
SolutionIntraperitoneal
PowderOral
Powder, for solutionOral
SolutionHemodialysis; Intravenous0.27 g/l
KitHemodialysis
SolutionIntravenous
InjectionIntravenous
SolutionHemodialysis0.257 g/l
LotionTopical
KitDental
LiquidOral
SolutionOral
Granule, effervescentOral1.415 g
Powder, for solutionOral56.6 g
Powder, for solutionNasal
Kit; powder, for solutionNasal
Kit; powder; solutionNasal
Injection, solutionIntravenous
TabletParenteral
Injection, solutionParenteral1 MEQ/1ML
Injection, solutionParenteral1.4 %
Injection, solutionParenteral5 %
Injection, solutionParenteral7.5 %
Injection, solutionParenteral8.4 G/100MG
Injection, solutionParenteral8.4 %
Injection, solution, concentrateIntravenous
Injection, solutionParenteral1 MEQ/ML
Injection, solutionParenteral1 MEQ/10ML
Injection, solutionParenteral
Injection, solution, concentrateIntravenous1 MEQ/ML
Injection, solution, concentrateIntravenous10 MEQ/10ML
InjectionIntravenous84 mg/1mL
InjectionParenteral42 mg/1mL
InjectionParenteral84 mg/1mL
Injection, solutionIntravenous1 meq/1mL
Injection, solutionIntravenous42 mg/1mL
Injection, solutionIntravenous44.6 meq/50mL
Injection, solutionIntravenous75 mg/1mL
Injection, solutionIntravenous84 mg/1mL
PowderOral; Topical100 %
SolutionIntravenous42 mg/1mL
SolutionIntravenous84 mg/1mL
SolutionParenteral84 mg/1mL
Tablet
Tablet500 MG
TabletOral650 mg/1
Tablet, orally disintegratingOral650 mg/1
TabletOral648 mg/1
Tablet, solubleOral648 mg/1
TabletOral325 mg/1
Tablet, solubleOral324 mg/1
LiquidIntravenous50 mg / mL
SolutionIntravenous5 g / 100 mL
PowderOral2.52 g/2.52g
PowderOral2.6 g/2.6g
PowderOral2.616 g/2.616g
CapsuleOral500 mg
Powder, for solutionHemodialysis672 g / pck
PowderHemodialysis650 g / pck
LiquidIntravenous42 mg / mL
LiquidIntravenous75 mg / mL
LiquidIntravenous84 mg / mL
SolutionIntravenous4200 mg / 50 mL
SolutionIntravenous840 mg / 10 mL
SolutionIntravenous75 mg / mL
InjectionIntravenous8.4 g/100ml
SolutionIntravenous42 mg / mL
SolutionIntravenous84 mg / mL
InjectionIntravenous8.4 % w/v
InjectionIntravenous4.2 % w/v
TabletOral300 mg
TabletOral600 mg
PowderHemodialysis650 g / sachet
PowderHemodialysis
Powder, for solutionHemodialysis1100 g / cartridge
Powder, for solutionHemodialysis760 g / cartridge
SolutionExtracorporeal0.42 g/L
SolutionExtracorporeal
SolutionExtracorporeal
Solution
CapsuleOral
Injection, powder, for solutionIntravenous
Kit; powder, for solutionIntravenous
CreamTopical50 mg/1g
Capsule, gelatin coatedOral
Injection, solutionIntravenous840 mg/10ml
Granule, for solutionOral
Granule, effervescentOral0.72 g
TabletOral200 mg
TabletOral250 mg
KitNasal
Granule, for solutionNasal
Tablet, chewableOral
Syrup
Syrup50 mg/5ml
Suspension
Tablet300 mg
Solution0.6 g/5mL
Tablet, sugar coatedOral
Powder
Solution50 mg/5ml
Tablet650 mg
SolutionIntravenous75 mg/1ml
Tablet
Prices
Unit descriptionCostUnit
Golytely 236 gm Solution28.0USD bottle
Colyte 240 gm Solution26.0USD bottle
Golytely 227.1 gm Solution Packet21.85USD packet
Colyte-Flavored 240 gm Solution18.17USD bottle
Elliotts b solution ampule4.71USD ml
Sodium bicarb 4.2% vial1.45USD ml
Neut 4% vial0.92USD ml
Bss plus eye solution0.2USD ml
Sodium bicarb 650 mg tablet0.07USD tablet
Antacid 650 mg tablet0.05USD tablet
Antacid 325 mg tablet0.04USD tablet
Sodium bicarb 325 mg tablet0.04USD tablet
Sodium bicarb 7.5% vial0.04USD ml
Sodium bicarbonate powder0.03USD g
Sodium bicarb 8.4% vial0.02USD ml
Sodium bicarbonate 5% inj0.02USD ml
Colyte with flavor packets0.01USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)Region
US6489346No2002-12-032016-07-16US flag
US6699885No2004-03-022016-07-16US flag
USRE45198No2014-10-142016-07-16US flag
US6645988No2003-11-112016-07-16US flag
US7399772No2008-07-152016-07-16US flag
US5945449No1999-08-312017-10-31US flag
US7300674No2007-11-272023-03-04US flag
US7291324No2007-11-062022-10-22US flag
US5840737No1998-11-242016-07-15US flag
US6780882No2004-08-242016-07-15US flag
US7084130No2006-08-012021-11-29US flag
US10751333No2020-08-252039-07-16US flag
US11103492No2021-08-312039-07-16US flag
US11633478No2019-07-162039-07-16US flag
US11771686No2020-03-012040-03-01US flag

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)Decomposes around 50 °CNot Available
water solubility1E+005 mg/L (at 25 °C)MERCK INDEX (1996)
pKa6.3Not Available
Predicted Properties
PropertyValueSource
Water Solubility764.0 mg/mLALOGPS
logP-0.06ALOGPS
logP0.25Chemaxon
logS0.96ALOGPS
pKa (Strongest Acidic)3.5Chemaxon
Physiological Charge-1Chemaxon
Hydrogen Acceptor Count3Chemaxon
Hydrogen Donor Count1Chemaxon
Polar Surface Area60.36 Å2Chemaxon
Rotatable Bond Count0Chemaxon
Refractivity20.34 m3·mol-1Chemaxon
Polarizability3.86 Å3Chemaxon
Number of Rings0Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.9292
Blood Brain Barrier+0.936
Caco-2 permeable-0.5321
P-glycoprotein substrateNon-substrate0.8785
P-glycoprotein inhibitor INon-inhibitor0.9903
P-glycoprotein inhibitor IINon-inhibitor0.9931
Renal organic cation transporterNon-inhibitor0.9563
CYP450 2C9 substrateNon-substrate0.8326
CYP450 2D6 substrateNon-substrate0.9017
CYP450 3A4 substrateNon-substrate0.8144
CYP450 1A2 substrateNon-inhibitor0.9053
CYP450 2C9 inhibitorNon-inhibitor0.9337
CYP450 2D6 inhibitorNon-inhibitor0.9401
CYP450 2C19 inhibitorNon-inhibitor0.9461
CYP450 3A4 inhibitorNon-inhibitor0.9774
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9911
Ames testNon AMES toxic0.9285
CarcinogenicityNon-carcinogens0.5181
BiodegradationReady biodegradable0.9636
Rat acute toxicity1.9204 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9596
hERG inhibition (predictor II)Non-inhibitor0.9866
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-001l-9000000000-1db7da28c301538fe679
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-115.22661
predicted
DeepCCS 1.0 (2019)
[M+H]+117.1888
predicted
DeepCCS 1.0 (2019)
[M+Na]+125.864746
predicted
DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Kind
Small molecule
Organism
Not Available
Pharmacological action
Yes
Actions
Neutralizer
References
  1. Nudel DB, Peterson BJ, Buckley BJ, Kaplan NA, Weinhaouse E, Gootman N: Comparative effects of bicarbonate and dichloroacetate in newborn swine with hypoxic lactic acidosis. Dev Pharmacol Ther. 1990;15(2):86-93. [Article]
  2. Roderick P, Willis NS, Blakeley S, Jones C, Tomson C: Correction of chronic metabolic acidosis for chronic kidney disease patients. Cochrane Database Syst Rev. 2007 Jan 24;(1):CD001890. [Article]
  3. Balali-Mood M, Balali-Mood K: Neurotoxic disorders of organophosphorus compounds and their managements. Arch Iran Med. 2008 Jan;11(1):65-89. [Article]
  4. Vaughan-Jones RD, Spitzer KW: Role of bicarbonate in the regulation of intracellular pH in the mammalian ventricular myocyte. Biochem Cell Biol. 2002;80(5):579-96. [Article]
  5. Levraut J, Giunti C, Ciebiera JP, de Sousa G, Ramhani R, Payan P, Grimaud D: Initial effect of sodium bicarbonate on intracellular pH depends on the extracellular nonbicarbonate buffering capacity. Crit Care Med. 2001 May;29(5):1033-9. [Article]

Transporters

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Sodium:bicarbonate symporter activity
Specific Function
Electrogenic sodium/bicarbonate cotransporter with a Na(+):HCO3(-) stoichiometry varying from 1:2 to 1:3. May regulate bicarbonate influx/efflux at the basolateral membrane of cells and regulate in...
Gene Name
SLC4A4
Uniprot ID
Q9Y6R1
Uniprot Name
Electrogenic sodium bicarbonate cotransporter 1
Molecular Weight
121459.38 Da
References
  1. Bernardo AA, Bernardo CM, Espiritu DJ, Arruda JA: The sodium bicarbonate cotransporter: structure, function, and regulation. Semin Nephrol. 2006 Sep;26(5):352-60. [Article]
  2. Kurtz I, Petrasek D, Tatishchev S: Molecular mechanisms of electrogenic sodium bicarbonate cotransport: structural and equilibrium thermodynamic considerations. J Membr Biol. 2004 Jan 15;197(2):77-90. [Article]
  3. Soleimani M: Functional and molecular properties of Na+:HCO-3 cotransporters (NBC). Minerva Urol Nefrol. 2003 Jun;55(2):131-40. [Article]
  4. Soleimani M: Na+:HCO3- cotransporters (NBC): expression and regulation in the kidney. J Nephrol. 2002 Mar-Apr;15 Suppl 5:S32-40. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Sodium:bicarbonate symporter activity
Specific Function
Electroneutral sodium- and bicarbonate-dependent cotransporter with a Na(+):HCO3(-) 1:1 stoichiometry. Regulates intracellular pH and may play a role in bicarbonate salvage in secretory epithelia. ...
Gene Name
SLC4A7
Uniprot ID
Q9Y6M7
Uniprot Name
Sodium bicarbonate cotransporter 3
Molecular Weight
136042.595 Da
References
  1. Bernardo AA, Bernardo CM, Espiritu DJ, Arruda JA: The sodium bicarbonate cotransporter: structure, function, and regulation. Semin Nephrol. 2006 Sep;26(5):352-60. [Article]
  2. Kurtz I, Petrasek D, Tatishchev S: Molecular mechanisms of electrogenic sodium bicarbonate cotransport: structural and equilibrium thermodynamic considerations. J Membr Biol. 2004 Jan 15;197(2):77-90. [Article]
  3. Soleimani M: Functional and molecular properties of Na+:HCO-3 cotransporters (NBC). Minerva Urol Nefrol. 2003 Jun;55(2):131-40. [Article]
  4. Soleimani M: Na+:HCO3- cotransporters (NBC): expression and regulation in the kidney. J Nephrol. 2002 Mar-Apr;15 Suppl 5:S32-40. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Sodium:bicarbonate symporter activity
Specific Function
Mediates electroneutral sodium- and carbonate-dependent chloride-HCO3(-) exchange with a Na(+):HCO3(-) stoichiometry of 2:1. Plays a major role in pH regulation in neurons. May be involved in cell ...
Gene Name
SLC4A8
Uniprot ID
Q2Y0W8
Uniprot Name
Electroneutral sodium bicarbonate exchanger 1
Molecular Weight
122936.66 Da
References
  1. Bernardo AA, Bernardo CM, Espiritu DJ, Arruda JA: The sodium bicarbonate cotransporter: structure, function, and regulation. Semin Nephrol. 2006 Sep;26(5):352-60. [Article]
  2. Kurtz I, Petrasek D, Tatishchev S: Molecular mechanisms of electrogenic sodium bicarbonate cotransport: structural and equilibrium thermodynamic considerations. J Membr Biol. 2004 Jan 15;197(2):77-90. [Article]
  3. Soleimani M: Functional and molecular properties of Na+:HCO-3 cotransporters (NBC). Minerva Urol Nefrol. 2003 Jun;55(2):131-40. [Article]
  4. Soleimani M: Na+:HCO3- cotransporters (NBC): expression and regulation in the kidney. J Nephrol. 2002 Mar-Apr;15 Suppl 5:S32-40. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Sodium:bicarbonate symporter activity
Specific Function
Mediates sodium- and bicarbonate-dependent electrogenic sodium bicarbonate cotransport, with a Na(+):HCO3(-) stoichiometry of 2:1. May have a housekeeping function in regulating the pH of tissues i...
Gene Name
SLC4A5
Uniprot ID
Q9BY07
Uniprot Name
Electrogenic sodium bicarbonate cotransporter 4
Molecular Weight
126254.04 Da
References
  1. Bernardo AA, Bernardo CM, Espiritu DJ, Arruda JA: The sodium bicarbonate cotransporter: structure, function, and regulation. Semin Nephrol. 2006 Sep;26(5):352-60. [Article]
  2. Kurtz I, Petrasek D, Tatishchev S: Molecular mechanisms of electrogenic sodium bicarbonate cotransport: structural and equilibrium thermodynamic considerations. J Membr Biol. 2004 Jan 15;197(2):77-90. [Article]
  3. Soleimani M: Functional and molecular properties of Na+:HCO-3 cotransporters (NBC). Minerva Urol Nefrol. 2003 Jun;55(2):131-40. [Article]
  4. Soleimani M: Na+:HCO3- cotransporters (NBC): expression and regulation in the kidney. J Nephrol. 2002 Mar-Apr;15 Suppl 5:S32-40. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Sodium:bicarbonate symporter activity
Specific Function
Electrogenic sodium/bicarbonate cotransporter in exchange for intracellular chloride. Plays an important role in regulating intracellular pH (By similarity).
Gene Name
SLC4A10
Uniprot ID
Q6U841
Uniprot Name
Sodium-driven chloride bicarbonate exchanger
Molecular Weight
125945.115 Da
References
  1. Bernardo AA, Bernardo CM, Espiritu DJ, Arruda JA: The sodium bicarbonate cotransporter: structure, function, and regulation. Semin Nephrol. 2006 Sep;26(5):352-60. [Article]
  2. Kurtz I, Petrasek D, Tatishchev S: Molecular mechanisms of electrogenic sodium bicarbonate cotransport: structural and equilibrium thermodynamic considerations. J Membr Biol. 2004 Jan 15;197(2):77-90. [Article]
  3. Soleimani M: Functional and molecular properties of Na+:HCO-3 cotransporters (NBC). Minerva Urol Nefrol. 2003 Jun;55(2):131-40. [Article]
  4. Soleimani M: Na+:HCO3- cotransporters (NBC): expression and regulation in the kidney. J Nephrol. 2002 Mar-Apr;15 Suppl 5:S32-40. [Article]

Drug created at July 08, 2007 16:59 / Updated at March 18, 2024 16:48